| Literature DB >> 29625858 |
Richa Shrivastava1, Mohammad Asif2, Varsha Singh2, Parul Dubey3, Showkat Ahmad Malik2, Mehraj-U-Din Lone2, Brij Nath Tewari3, Khemraj Singh Baghel2, Subhashis Pal4, Geet Kumar Nagar4, Naibedya Chattopadhyay4, Smrati Bhadauria5.
Abstract
Oncostatin M (OSM), an inflammatory cytokine belonging to the interleukin-6 (IL-6) superfamily, plays a vital role in multitude of physiological and pathological processes. Its role in breast tumor progression and metastasis to distant organs is well documented. Recent reports implicate OSM in macrophage M2 polarization, a key pro-tumoral phenomenon. M2 polarization of macrophages is believed to promote tumor progression by potentiating metastasis and angiogenesis. In the current study, we delineated the mechanism underlying OSM induced macrophage M2 polarization. The findings revealed that OSM skews macrophages towards an M2 polarized phenotype via mTOR signaling complex 2 (mTORC2). mTORC2 relays signals through two effector kinases i.e. PKC-α and Akt. Our results indicated that mTORC2 mediated M2 polarization of macrophages is not dependent on PKC-α and is primarily affected via Akt, particularly Akt1. In vivo studies conducted on 4T1/BALB/c mouse orthotropic model of breast cancer further corroborated these observations wherein i.v. reintroduction of mTORC2 abrogated monocytes into orthotropic mouse model resulted in diminished acquisition of M2 specific attributes by tumor associated macrophages. Metastasis to distant organs like lung, liver and bone was reduced as evident by decrease in formation of focal metastatic lesions in mTORC2 abrogated monocytes mice. Our study pinpoints key role of mTORC2-Akt1 axis in OSM induced macrophage polarization and suggests for possible usage of Oncostatin-M blockade and/or selective mTORC2 inhibition as a potential anti-cancer strategy particularly with reference to metastasis of breast cancer to distant organs such as lung, liver and bone.Entities:
Keywords: Akt; Hypoxia; M2 polarization; Metastasis; Oncostatin M; mTORC2
Mesh:
Substances:
Year: 2018 PMID: 29625858 DOI: 10.1016/j.cyto.2018.03.032
Source DB: PubMed Journal: Cytokine ISSN: 1043-4666 Impact factor: 3.861